Rocket Pharmaceuticals Inc Dossier - Source-backed chat

Rocket Pharmaceuticals Inc

RCKTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.65

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.59Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $284.3M

Enterprise Value $84.6M

Shares Outstanding 114.9M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Rocket Pharmaceuticals (RCKT) has successfully transitioned to a commercial-stage genomic medicine company following the FDA's accelerated approval of KRESLADI for severe LAD-I in March 2026. The subsequent $180 million monetization of its Rare Pediatric Disease Priority Review Voucher (PRV) has significantly de-risked its balance sheet, extending its cash runway into Q2 2028. However, near-term commercial revenues from KRESLADI are expected to be modest due to the ultra-rare nature of the disease. The company's valuation is heavily tied to its high-value cardiovascular pipeline, led by RP-A501 for Danon Disease. While the resumption of the pivotal Phase 2 trial under a recalibrated lower dose is a positive step, the program carries substantial clinical and execution risks following previous safety setbacks. Given the binary nature of gene therapy development and the current bearish technical trend of the stock, a Hold rating is recommended until further clinical data from the Danon program is presented in the second half of 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$8.84

High · most bullish analyst$15.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0020%

The bear case is triggered by further safety setbacks in the RP-A501 Danon Disease trial, such as recurrent serious adverse events or another clinical hold, which would severely damage the company's core valuation driver. Additionally, slow commercial uptake of KRESLADI due to payer resistance or high manufacturing costs could accelerate cash burn, forcing highly dilutive equity raises before 2028.

Base CaseCentral scenario

$9.3950%

The base case assumes KRESLADI launches successfully in Q4 2026 but generates modest initial revenues due to the small patient population. The pivotal Phase 2 trial of RP-A501 in Danon Disease progresses on track with the initial three-patient cohort, showing stable safety and efficacy, but regulatory filing timelines remain extended. The company maintains its cash runway into 2028 without immediate dilutive financing, keeping the valuation stable as the market awaits late-stage clinical readouts.

Bull CaseUpside scenario

$16.0030%

The bull case is driven by the successful clinical execution and eventual approval of RP-A501 for Danon Disease, which represents a multi-billion dollar market opportunity with no approved curative therapies. Under this scenario, the recalibrated dose demonstrates robust efficacy and a clean safety profile, leading to rapid FDA approval. Additionally, KRESLADI achieves strong market penetration and favorable pricing, while the company successfully out-licenses its legacy hematology programs (Fanconi Anemia and PKD) to secure further non-dilutive capital.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transitioned to a commercial-stage company with the FDA approval of KRESLADI in March 2026.
Strong balance sheet with pro forma cash of ~$322.6 million, extending the runway into Q2 2028 following the $180 million PRV sale.
First-mover advantage in genetic cardiology with RP-A501 for Danon Disease, targeting a high unmet need with billion-dollar potential.
State-of-the-art, in-house 103,000-square-foot manufacturing facility that reduces reliance on CDMOs and lowers long-term COGS.

Key Investment Risks

High clinical and regulatory risk associated with gene therapies, as evidenced by the previous clinical hold on the Danon Disease trial.
Limited near-term commercial revenue potential from KRESLADI due to the ultra-rare nature of severe LAD-I.
History of pipeline restructuring and program withdrawals, including the voluntary withdrawal of the Fanconi Anemia BLA in late 2025.
Payer access and reimbursement hurdles for high-cost, one-time curative genetic therapies.

Thesis Invalidation Triggers

Another FDA clinical hold or severe safety signal in the RP-A501 Danon Disease trial.
Failure to launch KRESLADI by the end of 2026 or inability to secure insurance coverage.
Significant acceleration in cash burn that shortens the runway to under 18 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.